Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE -200.9%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $1M | $340467 | $733017 | $61M | — | — | — |
| Enterprise Value | $-58745 | $-1016823 | $-770445 | $59M | — | — | — |
| P/E Ratio → | -0.14 | — | — | — | — | — | — |
| P/S Ratio | 1.29 | 0.34 | 1.21 | 238.95 | — | — | — |
| P/B Ratio | 0.32 | 0.10 | 0.19 | 12.63 | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -1.01 | -1.27 | 231.19 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 22.3% | 22.3% | 36.7% | -87.1% | -93.7% | 26.7% | 67.8% |
| Operating Margin | -771.6% | -771.6% | -1599.0% | -2032.8% | -784.2% | -96.9% | -19.2% |
| Net Profit Margin | -732.8% | -732.8% | -1308.0% | -1485.1% | -2769.5% | -366.4% | -139.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -200.9% | -200.9% | -181.6% | -78.5% | — | — | — |
| ROA | -132.5% | -132.5% | -117.4% | -82.9% | -459.5% | -212.6% | -116.4% |
| ROIC | -260.1% | -260.1% | -276.0% | -928.6% | — | -119.4% | -35.7% |
| ROCE | -203.5% | -203.5% | -214.7% | -104.2% | — | -116.4% | -35.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.04 | 0.04 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.40 | -0.38 | -0.41 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -943.05 | -943.05 | -1004.49 | -0.67 | -0.55 | -0.34 | -0.14 |
Net cash position: cash ($2M) exceeds total debt ($152775)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 2.66 | 2.66 | 3.25 | 2.55 | 0.05 | 1.85 | 1.70 |
| Quick Ratio | 2.30 | 2.30 | 2.98 | 2.39 | 0.02 | 0.77 | 0.98 |
| Cash Ratio | 1.49 | 1.49 | 2.04 | 0.76 | 0.01 | 0.18 | 0.13 |
| Asset Turnover | — | 0.19 | 0.11 | 0.03 | 0.17 | 0.83 | 0.84 |
| Inventory Turnover | 1.19 | 1.19 | 0.87 | 1.02 | 0.83 | 1.23 | 0.68 |
| Days Sales Outstanding | — | 185.01 | 292.41 | 332.99 | 75.16 | 46.04 | 143.80 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $670211 | $113646 | $990070 | $1M | $1M | $1M |
Imminent Liquidity Exhaustion
According to recent market data, SXTP trades at a price-to-sales multiple of 1.29, a valuation that appears to heavily discount the company's future growth prospects due to the persistent inability to convert its niche regulatory monopoly into a sustainable, profit-generating commercial enterprise for its shareholders.
The current P/S ratio suggests that investors are pricing the firm as a distressed asset rather than a growth-stage biotech, likely due to the lack of a clear path to positive earnings. This valuation multiple implies that the market remains skeptical of the company's ability to scale Arakoda's market share sufficiently to overcome its high fixed-cost base.
Based on reported financial statements, the company's ROIC has consistently remained in negative territory, reaching -87.8% in 2026Q1, which indicates that the capital deployed into the business is currently destroying value rather than compounding returns for the firm's stakeholders in the current operating environment.
The persistent negative ROIC highlights a fundamental disconnect between the capital invested in regulatory and commercial infrastructure and the actual returns generated from product sales. This trend suggests that the company is struggling to achieve the necessary economies of scale to justify its ongoing R&D and operational expenditures.
As reported in recent quarterly filings, the company's cash conversion cycle remains highly erratic, with a 2026Q1 figure of -489 days, suggesting that the firm faces significant challenges in managing its inventory and accounts payable in a way that supports a stable, predictable cash flow profile.
The extreme volatility in the cash conversion cycle, particularly the high days inventory outstanding, implies that the company may be holding excess stock that is not moving through the distribution channel as quickly as anticipated. This inefficiency forces the firm to rely on external financing to bridge the gap between production costs and actual cash collection.
Based on the company's reported figures, the current ratio of 3.34 in 2026Q1 masks the underlying reality of a rapidly depleting cash balance, which warrants further investigation into whether the firm can sustain its current operating burn rate without seeking immediate and dilutive external capital infusions.
While the current ratio appears superficially healthy, the absolute cash levels are insufficient to support the company's high operating losses over the long term. Investors should monitor the cash runway closely, as the current liquidity position provides little buffer against potential regulatory or market-driven disruptions to Arakoda's sales.
The market's reliance on P/S multiples to value SXTP is fundamentally flawed, as it obscures the company's massive operating losses and the critical importance of cash burn rates in determining the survival of early-stage biotech firms with single-product revenue streams and high regulatory overhead costs.
Instead of revenue-based multiples, analysts should prioritize 'time-to-exhaustion' metrics and cash-burn-to-liquidity ratios to assess the firm's viability. Focusing on sales growth ignores the reality that each additional dollar of revenue currently comes at a disproportionately high cost, making traditional valuation metrics misleading for this specific business model.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SXTP stock.
60 Degrees Pharmaceuticals, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
60 Degrees Pharmaceuticals, Inc.'s return on equity (ROE) is -200.9%. The historical average is -153.7%.
Based on historical data, 60 Degrees Pharmaceuticals, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
60 Degrees Pharmaceuticals, Inc. has 22.3% gross margin and -771.6% operating margin.